title: Therapeutic effect of autologous bone marrow-derived liver stem cells transplantation in hepatitis B virus-induced liver cirrhosis.
abstract: OBJECTIVE
  To determine the safety, feasibility and therapeutic effect of in vitro-expanded autologous bone marrow-derived liver stem cells (BMDLSC) transplantation in cirrhotic patients following chronic hepatitis B virus infection.
  
  
  METHODS
  Twelve patients with post-hepatitic cirrhosis and portal hypertension who required splenectomy with periesophagogastric devascularization were included and were divided into two groups. Group I included six patients who received autologous BMDLSC infusion via the hepatic artery after in vitro expansion for 7 days. Group II (control group) included six patients who received normal saline infusion via the same route during splenectomy with periesophagogastric devascularization. The therapeutic effects were compared 3 months later. Patients in Group I were followed-up for 24 months after transplantation.
  
  
  RESULTS
  There were no adverse effects during short- and long-term follow-ups. Three months after the operation, patients who received BMDLSC infusion showed better hepatic function than those who received saline infusion (p<0.05). Patients in Group I showed stable liver function parameters with no complications during the 24-month follow-up period.
  
  
  CONCLUSIONS
  Transplantation of in vitro-expanded autologous BMDLSC via the hepatic artery is a safe and effective treatment for decompensated liver cirrhosis.
authors.affiliation: Department of Hepatobiliary Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China.
authors.forename: XinXin
authors.initials: X
authors.lastname: Liao
authors.forename: Jie Yuan
authors.initials: JY
authors.lastname: AnCheng
authors.forename: Qin Jie
authors.initials: QJ
authors.lastname: Zhou
authors.forename: CaiXian
authors.initials: C
authors.lastname: Liao
mesh_terms: D000328:Adult; D015415:Biomarkers / Q000097:blood; D016026:Bone Marrow Transplantation / Q000009:adverse effects; D002478:Cells, Cultured; D005260:Female; D006499:Hepatic Artery; D019694:Hepatitis B, Chronic / Q000150:complications*; D022781:Hepatocytes / Q000378:metabolism / Q000637:transplantation*; D006801:Humans; D006975:Hypertension, Portal / Q000601:surgery / Q000821:virology; D007261:Infusions, Intra-Arterial; D008103:Liver Cirrhosis / Q000097:blood / Q000175:diagnosis / Q000601:surgery* / Q000821:virology; D008111:Liver Function Tests; D008297:Male; D008875:Middle Aged; D013156:Splenectomy; D033581:Stem Cell Transplantation / Q000009:adverse effects; D013997:Time Factors; D014182:Transplantation, Autologous; D016896:Treatment Outcome
chemical_list: D015415:Biomarkers